Log in or Sign up for Free to view tailored content for your specialty!
Liver/Biliary Disorders News
Multiparametric MRI liver biomarkers predict those ‘likely to achieve’ MASH resolution
Changes in MRI-derived markers of iron-corrected T1 mapping and liver fat content appear effective at predicting histological response among patients treated for metabolic dysfunction-associated steatohepatitis, according to researchers.
Waitlist priority, quality donors tied to better outcomes in pediatric acute liver failure
Over three decades, changes to organ allocation policies were associated with reduced waitlist mortality and increased rates of liver transplant among children with pediatric acute liver failure, according to research in JAMA Surgery.
Log in or Sign up for Free to view tailored content for your specialty!
Drug rivals face off in PBC after FDA hands down 2 new approvals, 1 advisory snub
The long-stagnant primary biliary cholangitis drug market has seen renewed attention in the past 3 months with the addition of two FDA-approved therapy options as well as a costly ruling from an FDA advisory committee.
Hispanic, Asian populations in US at highest risk for alcohol-associated liver disease
Significant differences in alcohol use, alcohol-related mortality and liver transplant rate by race and ethnicity underscore the need for “tailored approaches to managing” alcohol-related liver disease in the U.S., according to a researcher.
Immunotherapy may make transplant possible in late-stage liver cancer
Immunotherapy treatment may make liver transplant viable for patients with later-stage hepatocellular carcinoma provided they adhere to a 3-month waiting period, according to study results.
FDA grants breakthrough designation to survodutide for treatment of MASH
The FDA has granted breakthrough therapy designation to Boehringer Ingelheim’s survodutide for the treatment of adult patients with noncirrhotic metabolic dysfunction-associated steatohepatitis and moderate or advanced fibrosis.
‘Call to action’: Variation in cirrhosis infections support streamlined antibiotic use
Significant variations in global rates of infection, culture-positivity and drug resistance serve as a “call to action” to streamline antibiotic use and improve outcomes among inpatients with cirrhosis, according to researchers.
Hepatic steatosis identified in more than half of younger adults without history of MASLD
Hepatic steatosis was prevalent among 52% of adults with or without type 2 diabetes and no known history of metabolic dysfunction-associated steatotic liver disease, according to findings published in Obesity.
FDA grants breakthrough status to Sagimet’s denifanstat to treat MASH with fibrosis
The FDA granted breakthrough designation to Sagimet Biosciences’ denifanstat for the treatment of patients with metabolic dysfunction-associated steatohepatitis and moderate to advanced fibrosis, according to a company press release.
Mental health concerns reduce likelihood of hepatology referral in alcohol use disorder
Nearly two-thirds of patients with excessive alcohol use and a high fibrosis-4 index were not referred for liver-related care, with fewer referrals among those with mental health disorders or alcohol-related mental health hospitalizations.
-
Headline News
Rise in alcohol use during pandemic endures as 'an alarming public health issue'
November 14, 20242 min read -
Headline News
AI identified patient messages sent by proxies, but also broke confidentiality
November 14, 20242 min read -
Headline News
Diabetes inequities persist worldwide, especially for low-, middle-income countries
November 14, 20243 min read
-
Headline News
Rise in alcohol use during pandemic endures as 'an alarming public health issue'
November 14, 20242 min read -
Headline News
AI identified patient messages sent by proxies, but also broke confidentiality
November 14, 20242 min read -
Headline News
Diabetes inequities persist worldwide, especially for low-, middle-income countries
November 14, 20243 min read